J. Hugosson et al., THE RISK OF MALIGNANCY IN THE SURGICAL MARGIN AT RADICAL PROSTATECTOMY REDUCED ALMOST 3-FOLD IN PATIENTS GIVEN NEOADJUVANT HORMONE-TREATMENT, European urology, 29(4), 1996, pp. 413-419
Objectives: To investigate the outcome of neo-adjuvant hormone treatme
nt before radical prostatectomy regarding local tumour extension, peri
-operative blood loss and operation time. Patients: Of 111 surgically
treated patients with prostate cancer (T1(b-)T3(a), N-0, M(0), G(1-3))
, 55 were randomised to immediate radical prostatectomy and 56 to 3 mo
nths of neo-adjuvant treatment with triptorelin (3.75 mg i.m. every 28
days) and cyproterone acetate (50 mg b.i.d. for 3 weeks to prevent fl
are). Results: No differences were found in blood loss or operation ti
me but patients who had neo-adjuvant treatment had a significantly low
er frequency of positive margins (41 vs. 23%, p = 0.013). Conclusion:
Neo-adjuvant treatment does not facilitate radical prostatectomy but m
ay improve the chance of local cure. This must, however, be documented
with long-term follow-up in randomised patients.